Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy.

Witold Zgodziński, Ewelina Grywalska, Agata Surdacka, Krzysztof Zinkiewicz, Marek Majewski, Dariusz Szczepanek, Grzegorz Wallner, Jacek Roliński
Author Information
  1. Witold Zgodziński: 2 Department of General, Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Lublin, Poland.
  2. Ewelina Grywalska: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.
  3. Agata Surdacka: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.
  4. Krzysztof Zinkiewicz: 2 Department of General, Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Lublin, Poland.
  5. Marek Majewski: 2 Department of General, Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Lublin, Poland.
  6. Dariusz Szczepanek: Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Lublin, Poland.
  7. Grzegorz Wallner: 2 Department of General, Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Lublin, Poland.
  8. Jacek Roliński: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.

Abstract

INTRODUCTION: Gastric cancer (GC) is one of the leading causes of cancer death worldwide. The membrane glycoprotein CD200, widely expressed on multiple cells/tissues, uses a structurally similar receptor (CD200R), delivering immunoregulatory signals. There is evidence that CD200/CD200R signaling suppresses anti-tumor responses in different types of malignancies. Little is known about the CD200/CD200R pathway in GC. The aim of the study was to evaluate the frequencies of CD200+ and CD200R+ lymphocytes in patients with GC.
MATERIAL AND METHODS: Forty patients primarily diagnosed with GC and 20 healthy volunteers (control group) were enrolled. The viable peripheral blood lymphocytes underwent labeling with fluorochrome-conjugated monoclonal antibodies and were analyzed using a flow cytometer.
RESULTS: In the GC group, the percentages of T CD3+, CD3+/CD4+, and CD3+/CD8+ cells expressing CD200 antigen were higher than in the control group ( < 0.00013, < 0.0004, and < 0.0006, respectively). In the GC group, the frequencies of T CD3+, CD3+/CD4+ and CD3+/CD8+ cells expressing CD200R were lower than in the control group ( < 0.0009, < 0.004, and < 0.002, respectively). The percentage of B CD19+/CD200+ lymphocytes was higher in GC patients than in the control group ( < 0.00005). Lower frequency of B CD19+/CD200R+ cells was observed in GC patients compared to the control group ( < 0.0001). No differences in the frequencies of CD200+ and CD200R+ lymphocytes were found in relation to either UICC stage or histological grading of the tumors.
CONCLUSIONS: For GC pathogenesis, deregulation of the CD200/CD200R axis is important. High percentages of lymphocytes with CD200 expression may contribute to the continuous T cell activation and development of chronic inflammation and influence gastric carcinogenesis.

Keywords

References

  1. J Immunol Res. 2014;2014:215471 [PMID: 24991577]
  2. Breast Cancer Res Treat. 2011 Nov;130(1):49-60 [PMID: 21165772]
  3. Immunology. 2001 Feb;102(2):173-9 [PMID: 11260322]
  4. Clin Chim Acta. 2012 Oct 9;413(19-20):1495-9 [PMID: 22713512]
  5. Clin Lab. 2013;59(3-4):429-33 [PMID: 23724636]
  6. Oncogene. 2010 Feb 25;29(8):1093-102 [PMID: 19946335]
  7. J Leukoc Biol. 2010 Aug;88(2):361-72 [PMID: 20442224]
  8. Immunol Rev. 2006 Oct;213:131-45 [PMID: 16972901]
  9. J Immunol. 2016 Aug 15;197(4):1489-97 [PMID: 27385779]
  10. Oncogene. 2012 Jun 14;31(24):2979-88 [PMID: 22020332]
  11. J Immunol. 2007 May 1;178(9):5595-605 [PMID: 17442942]
  12. J Immunol. 2008 Jan 15;180(2):699-705 [PMID: 18178807]
  13. J Surg Oncol. 2013 Apr;107(5):517-22 [PMID: 23129549]
  14. Biochem Soc Symp. 1986;51:149-57 [PMID: 2880589]
  15. Nat Rev Immunol. 2006 Apr;6(4):295-307 [PMID: 16557261]
  16. Scand J Immunol. 2013 Jul;78(1):1-7 [PMID: 23298229]
  17. J Clin Invest. 2007 Dec;117(12):3922-9 [PMID: 18008004]
  18. Blood. 2006 Dec 15;108(13):4194-7 [PMID: 16946299]
  19. Oncotarget. 2015 Oct 20;6(32):33486-99 [PMID: 26378021]
  20. Annu Rev Immunol. 2004;22:329-60 [PMID: 15032581]
  21. Mod Pathol. 2003 Jul;16(7):641-51 [PMID: 12861059]
  22. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [PMID: 21296855]
  23. Arch Med Sci. 2017 Oct;13(6):1373-1382 [PMID: 29181068]
  24. J Investig Med. 2012 Jan;60(1):56-61 [PMID: 22064604]
  25. Cancer Res. 2010 Apr 1;70(7):2962-72 [PMID: 20332223]

Word Cloud

Created with Highcharts 10.0.0GC<0lymphocytesgroupCD200controlCD200RpatientscancerCD200/CD200RfrequenciesTcellsgastricCD200+CD200R+percentagesCD3+CD3+/CD4+CD3+/CD8+expressinghigherrespectivelyBINTRODUCTION:Gastriconeleadingcausesdeathworldwidemembraneglycoproteinwidelyexpressedmultiplecells/tissuesusesstructurallysimilarreceptordeliveringimmunoregulatorysignalsevidencesignalingsuppressesanti-tumorresponsesdifferenttypesmalignanciesLittleknownpathwayaimstudyevaluateMATERIALANDMETHODS:Fortyprimarilydiagnosed20healthyvolunteersenrolledviableperipheralbloodunderwentlabelingfluorochrome-conjugatedmonoclonalantibodiesanalyzedusingflowcytometerRESULTS:antigen0001300040006lower0009004002percentageCD19+/CD200+00005LowerfrequencyCD19+/CD200R+observedcompared0001differencesfoundrelationeitherUICCstagehistologicalgradingtumorsCONCLUSIONS:pathogenesisderegulationaxisimportantHighexpressionmaycontributecontinuouscellactivationdevelopmentchronicinflammationinfluencecarcinogenesisSurfaceantigensadvancedcancer:newpotentialtargetimmunotherapymolecules

Similar Articles

Cited By